Business Wire

Verimatrix: Survey of Mobile Banking Security Experts Reveals Questionable Practices

9.6.2021 18:45:00 EEST | Business Wire | Press release

Share

Regulatory News:

Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced the release of its commissioned ISMG report titled, “The State of Mobile Banking App Security.” The full report is available for download at www.verimatrix.com/ebooks/state-of-mobile-security.

Featuring responses from 150 financial services security professionals throughout the United States, Canada and EMEA, the report’s survey illustrates a notable disconnect between the importance placed on mobile apps and the attention it receives from the highest-level security professionals. Although 82 percent of respondents said securing the mobile channel was important or very important, just over half of CISOs report evaluating, influencing or deciding on mobile security.

More than 60 percent of respondents said they were confident about the level of security on their mobile apps, yet they admitted they outsourced mobile app development 50% of the time, or purchased a white label solution 19% of the time, meaning the chain of responsibility for app security is less verifiable than might be expected in the sector. A surprising 39% of respondents don't run vulnerability analysis and penetration tests on mobile channels.

In addition to tracking executive-level involvement and outsourcing trends, the report discusses the challenges surrounding developing and securing the mobile channel. It highlights banking security teams’ greatest concerns related to mobile banking as well as what types of mobile attacks are most prevalent and how today’s banking security executives are mitigating the risk.

“It’s clear that security professionals within the financial services sector understand just how critical mobile apps are to their business, but this must translate into more executive-level involvement when creating a strategy to protect their apps that ingest and deliver highly sensitive data,” said Asaf Ashkenazi, Chief Operating Officer at Verimatrix. “We’re pleased to sponsor this ISMG report that shows that words are one thing, deeds are quite another. Taking ownership of mobile app security early on is the key to secure users and save corporate reputations.”

A summary of top findings includes:

  • 82% of respondents consider securing the mobile channel to be important or very important for their financial institution
  • 69% perceive the mobile channel to be critical or very critical to their financial institution
  • 53% of CISOs are involved in evaluating, influencing or deciding on mobile security
  • Nearly 70% perceive the mobile channel to be critical or very critical for their financial institution
  • 60% are confident about the level of security on their mobile apps, and only 8% of those are extremely confident
  • Nearly 33% are worried or very worried about application/API hacks

About ISMG
Information Security Media Group (ISMG) is the world’s largest media organization devoted solely to information security and risk management. Each of our 28 media properties provides education, research and news that is specifically tailored to key vertical sectors including banking, healthcare and the public sector; geographies from North America to Southeast Asia; and topics such as data breach prevention, cyber risk assessment and fraud. Our annual global summit series connects senior security professionals with industry thought leaders to find actionable solutions for pressing cybersecurity challenges. Visit www.ismg.io.

About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. To learn more, visit www.verimatrix.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Verimatrix Investor Contact:
Richard Vacher Detournière
General Manager & Chief Financial Officer
+33 (0)4 42 905 905
finance@verimatrix.com

Verimatrix Media Contact:
Matthew Zintel
+1 281 444 1590
matthew.zintel@zintelpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo ® ) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 09:00:00 EEST | Press release

Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one of the largest real-world evaluations of mogamulizumab in Germany and add to the growing body of evidence supporting its use in routine clinical practice.1-3 Conducted as a company-sponsored, multicentric, non-interventional, combined retro-prospective real-world study across 18 centres throughout Germany, MINT brought together cutaneous T‑cell lymphoma (CTCL) specialists to evaluate treatment outcomes with mogamulizumab in a real-world setting, with time-to-next-treatment (TTNT) as the study’s primary endpoint.1 The study captured a broad and heterog

Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 09:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural next step for Megaport. “Portugal’s digital economy is rapidly growing, and infrastructure is at the heart of that transfor

Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 19:09:00 EEST | Press release

Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,

Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 13:30:00 EEST | Press release

As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged

Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye